Shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the twenty brokerages that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, six have given a hold recommendation, twelve have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $120.44.
Several equities analysts have commented on BNTX shares. Morgan Stanley dropped their target price on BioNTech from $114.00 to $106.00 and set an "overweight" rating for the company in a research report on Wednesday, November 4th. Citigroup lowered their price objective on BioNTech from $130.00 to $125.00 and set a "buy" rating for the company in a research report on Wednesday, August 5th. JPMorgan Chase & Co. lifted their price objective on BioNTech from $92.00 to $93.00 and gave the stock a "neutral" rating in a research note on Thursday. Berenberg Bank set a $140.00 target price on BioNTech in a report on Wednesday, September 16th. Finally, BMO Capital Markets cut BioNTech from an "outperform" rating to a "market perform" rating and reduced their target price for the company from $128.00 to $105.00 in a report on Tuesday, September 8th.
Read Our Latest Report on BioNTech
BioNTech Trading Down 0.7%
NASDAQ BNTX opened at $80.77 on Friday. The company has a market cap of $20.43 billion, a price-to-earnings ratio of -11.79 and a beta of 1.28. BioNTech has a twelve month low of $79.52 and a twelve month high of $124.00. The company has a quick ratio of 8.52, a current ratio of 8.55 and a debt-to-equity ratio of 0.01. The business's fifty day moving average is $91.52 and its 200 day moving average is $95.18.
Insider Transactions at BioNTech
In other news, CEO Ugur Sahin sold 72,000 shares of the business's stock in a transaction that occurred on Monday, October 5th. The shares were sold at an average price of $97.23, for a total value of $7,000,560.00. Following the transaction, the chief executive officer owned 108,209 shares in the company, valued at approximately $10,521,161.07. The trade was a 39.95% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 807,209 shares of company stock worth $79,246,837. 19.20% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On BioNTech
A number of hedge funds have recently bought and sold shares of BNTX. Flossbach Von Storch SE bought a new position in shares of BioNTech in the 2nd quarter worth about $207,142,000. First Trust Advisors LP boosted its position in shares of BioNTech by 116.0% during the 1st quarter. First Trust Advisors LP now owns 839,991 shares of the company's stock valued at $74,658,000 after purchasing an additional 451,124 shares in the last quarter. Assenagon Asset Management S.A. bought a new stake in shares of BioNTech during the 2nd quarter valued at about $39,385,000. Bank of America Corp DE grew its stake in BioNTech by 22.6% during the first quarter. Bank of America Corp DE now owns 903,029 shares of the company's stock worth $80,261,000 after purchasing an additional 166,432 shares during the period. Finally, Jump Financial LLC grew its stake in BioNTech by 1,483.5% during the third quarter. Jump Financial LLC now owns 172,600 shares of the company's stock worth $16,967,000 after purchasing an additional 161,700 shares during the period. Institutional investors own 15.52% of the company's stock.
About BioNTech
(
Get Free Report)
BioNTech SE is a biotechnology company based in Mainz, Germany. Founded in 2008, it develops medicines and vaccines, with a focus on immunotherapies for cancer and infectious diseases. The company's research uses technologies including messenger RNA (mRNA), antibodies, and cell-based therapies. Its best-known product is Comirnaty, an mRNA vaccine against COVID-19 developed and commercialized in partnership with Pfizer. BioNTech also has a broad oncology research and development portfolio. BioNTech works with partners to develop and distribute products internationally.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider BioNTech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioNTech wasn't on the list.
While BioNTech currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.